Recommendations for measuring HIV reservoir size in cure-directed clinical trials.

ABSTRACT: Therapeutic strategies are being clinically tested either to eradicate latent HIV reservoirs or to achieve virologic control in the absence of antiretroviral therapy. Attaining this goal will require a consensus on how best to measure the numbers of persistently infected cells with the potential to cause viral rebound after antiretroviral-therapy cessation in assessing the results of cure-directed strategies in vivo. Current measurements assess various aspects of the HIV provirus and its functionality and produce divergent results. Here, we provide recommendations from the BEAT-HIV Martin Delaney Collaboratory on which viral measurements should be prioritized in HIV-cure-directed clinical trials.

SUBMITTER: Abdel-Mohsen M 

PROVIDER: S-EPMC7703694 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature